FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease

Annovis Bio Inc ANVS has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's Disease (PD) as an offshoot of the Company's clinical program in Alzheimer's Disease (AD).

  • Following the Company's submission of Phase 2 data and the chronic toxicology data in animals, the Company requested directions to further develop Buntanetap in PD. 
  • The FDA guided initiating the Phase 3 clinical studies of Buntanetap for PD parallel with the AD program. 
  • Related: EXCLUSIVE: Annovis Bio's Parkinson's Candidate Improves Speed, Motor Function Vs. Placebo.
  • The agency detailed guidance on the specific endpoints, entry criteria, and further study parameters for two Phase 3 studies to support a broad indication for early and late PD.
  • Additionally, the FDA provided guidance on updating the existing Investigational New Drug Application (IND) for AD based on the successful Phase 2 study result and in preparation for an End of Phase 2 meeting on the AD indication.
  • Price Action: ANVS shares are down 4.12% at $13.25 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsParkinson’s DiseasePhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!